Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: ValuEngine, Inc.
$49.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Aquinox Pharmaceuticals Inc announces Initial public offering- Form S-1/A


Friday, 28 Feb 2014 06:13am EST 

Aquinox Pharmaceuticals Inc:Offering 3.7 mln shares of the company common stock.Initial public offering and no public market currently exists for stock.Expects initial public offering price to be between $10.00 and $12.00.Applies to list our common stock on the NASDAQ Global Market under the symbol AQXP.Estimates that the net proceeds from this offering will be about $35.4 mln, or about $41.1 mln if the underwriters exercise in full their option to purchase additional shares of common stock, assuming an initial public offering price of $11.00 per share.Expects to use the proceeds of this offering to conduct additional Phase 2 clinical trials to evaluate AQX-1125 as a potential treatment in indications beyond COPD and BPS/IC, to conduct additional toxicology studies, dose ranging studies.Proceeds to fund working capital, capital expenditures and other general corporate purposes which may include the acquisition or licensing of future product candidates, technologies, other assets or businesses. 

Company Quote

1.48
-0.03 -1.99%
27 Jul 2015